COMPASS Pathways Concludes Successful Series B Investment Round

COMPASS Pathways, a mental health care company, announced that it has completed a successful $80 million Series B investment round. This funding will expand upon COMPASS's lead program in psilocybin therapy for treatment-resistant depression, supporting research into additional indications for psilocybin therapy, advancing the company's preclinical pipeline, developing digital technologies, and establishing new academic and clinical research partnerships.

The Series B funding comes from existing investors, such as ATAI Life Sciences; and new investors, including the McQuade Center for Strategic Research and Development, LLC (a member of the global Otsuka family of pharmaceutical companies), Founders Fund, Able . . .